Financial Advocates Investment Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-16,633
| Closed | -$3.09M | – | 106 |
|
|
2025
Q2 | $3.09M | Buy |
16,633
+5,928
| +55% | +$1.1M | 0.25% | 88 |
|
|
2025
Q1 | $2.24M | Sell |
10,705
-16,263
| -60% | -$3.16M | 0.16% | 152 |
|
|
2024
Q4 | $4.79M | Sell |
26,968
-1,939
| -7% | -$356K | 0.27% | 79 |
|
|
2024
Q3 | $5.71M | Buy |
28,907
+194
| +0.7% | +$36.2K | 0.32% | 71 |
|
|
2024
Q2 | $4.92M | Sell |
28,713
-4,632
| -14% | -$767K | 0.31% | 74 |
|
|
2024
Q1 | $6.07M | Buy |
33,345
+501
| +2% | +$86.3K | 0.35% | 71 |
|
|
2023
Q4 | $5.09M | Sell |
32,844
-507
| -2% | -$73.9K | 0.33% | 71 |
|
|
2023
Q3 | $4.97M | Sell |
33,351
-213
| -0.6% | -$31.3K | 0.36% | 72 |
|
|
2023
Q2 | $4.52M | Buy |
33,564
+67
| +0.2% | +$9.82K | 0.32% | 77 |
|
|
2023
Q1 | $5.34M | Sell |
33,497
-1,318
| -4% | -$202K | 0.38% | 60 |
|
|
2022
Q4 | $5.63M | Buy |
34,815
+10,473
| +43% | +$1.61M | 0.42% | 53 |
|
|
2022
Q3 | $3.27M | Sell |
24,342
-8,694
| -26% | -$1.25M | 0.27% | 98 |
|
|
2022
Q2 | $5.06M | Buy |
33,036
+3,166
| +11% | +$484K | 0.41% | 59 |
|
|
2022
Q1 | $4.84M | Buy |
29,870
+993
| +3% | +$144K | 0.32% | 76 |
|
|
2021
Q4 | $3.91M | Buy |
28,877
+4,684
| +19% | +$553K | 0.25% | 101 |
|
|
2021
Q3 | $2.61M | Buy |
24,193
+2,146
| +10% | +$245K | 0.18% | 140 |
|
|
2021
Q2 | $2.44M | Sell |
22,047
-2,865
| -12% | -$323K | 0.16% | 151 |
|
|
2021
Q1 | $2.7M | Buy |
24,912
+178
| +0.7% | +$19K | 0.19% | 124 |
|
|
2020
Q4 | $2.65M | Buy |
24,734
+1,047
| +4% | +$101K | 0.18% | 123 |
|
|
2020
Q3 | $2.08M | Buy |
23,687
+3,553
| +18% | +$335K | 0.18% | 121 |
|
|
2020
Q2 | $1.98M | Buy |
20,134
+2,413
| +14% | +$212K | 0.19% | 127 |
|
|
2020
Q1 | $1.35M | Buy |
17,721
+3,010
| +20% | +$256K | 0.19% | 145 |
|
|
2019
Q4 | $1.3M | Buy |
14,711
+1,306
| +10% | +$108K | 0.14% | 172 |
|
|
2019
Q3 | $1.01M | Buy |
13,405
+2,150
| +19% | +$147K | 0.12% | 186 |
|
|
2019
Q2 | $818K | Buy |
11,255
+1,608
| +17% | +$126K | 0.09% | 210 |
|
|
2019
Q1 | $777K | Buy |
9,647
+104
| +1% | +$8.51K | 0.1% | 207 |
|
|
2018
Q4 | $880K | Buy |
9,543
+80
| +0.8% | +$7.04K | 0.12% | 184 |
|
|
2018
Q3 | $895K | Buy |
9,463
+268
| +3% | +$25.4K | 0.1% | 204 |
|
|
2018
Q2 | $856K | Buy |
9,195
+296
| +3% | +$28.9K | 0.1% | 204 |
|
|
2018
Q1 | $842K | Buy |
8,899
+2,967
| +50% | +$326K | 0.11% | 194 |
|
|
2017
Q4 | $574K | Buy |
+5,932
| New | +$559K | 0.08% | 237 |
|
Other funds holding ABBV
Financial Advocates Investment Management's ABBV Position: Q3 2025 in Review
Financial Advocates Investment Management sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 16,633 shares — an estimated $3.09M sold.
Financial Advocates Investment Management first reported a position in ABBV in Q4 2017 and held it in 31 quarters. The position peaked at $6.07M in Q1 2024. 3,910 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.
- Financial Advocates Investment Management reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
- Financial Advocates Investment Management sold 16,633 AbbVie shares in Q3 2025, an estimated $3.09M.
- Financial Advocates Investment Management first reported a position in AbbVie in Q4 2017 and held it in 31 quarters.
- Financial Advocates Investment Management's AbbVie position peaked at $6.07M in Q1 2024.
- 3,910 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.
Based on Financial Advocates Investment Management's 13F filing for Q3 2025, filed 6 Nov 2025.